What Is an MDL and How Does It Work?
A multidistrict litigation (MDL) is a federal procedural mechanism that consolidates related cases from courts across the country into a single district for coordinated pretrial proceedings. The Judicial Panel on Multidistrict Litigation (JPML) transfers cases sharing common factual questions to a single transferee court — in this case, the U.S. District Court for the District of Arizona — where one judge manages all pretrial matters for the entire litigation. The MDL does not merge the cases into a single lawsuit: each plaintiff retains their individual case, their individual claimed damages, and their individual right to a separate trial or settlement. The efficiency of the MDL comes from sharing discovery — documents, depositions of Becton Dickinson witnesses, and general causation expert work — across all cases rather than duplicating those efforts thousands of times.
The PowerPort MDL was established by JPML Order dated October 2022, consolidating cases pending in multiple federal districts. The MDL Judge issues Case Management Orders (CMOs) governing the schedule for plaintiff fact sheets, defendant document production, expert disclosure deadlines, and bellwether trial selection. The Plaintiffs' Steering Committee (PSC) — a group of experienced plaintiffs' attorneys appointed by the court — leads plaintiff-side discovery strategy on behalf of all plaintiffs. Individual plaintiffs' attorneys work with the PSC while maintaining their individual client relationships.
Where the MDL Stands as of Early 2026
As of early 2026, the Bard PowerPort MDL in the District of Arizona has grown to include thousands of plaintiffs with claims arising from catheter fracture, fragment embolization, infection, cardiac injury, and wrongful death. General causation discovery — addressing whether the PowerPort's polyurethane catheter is capable of fracturing and causing the injuries alleged — has proceeded with expert disclosures from both sides. Becton Dickinson has produced millions of pages of internal documents through the discovery process, including communications about the polyurethane degradation issue, adverse event reports submitted to the FDA under 21 CFR Part 803, and internal materials science testing data. The bellwether trial selection process, in which a pool of representative cases is selected for early trial to generate jury verdict data, is underway. Bellwether verdicts are expected to catalyze global settlement negotiations.
What Joining the MDL Means for Individual Plaintiffs
Filing a PowerPort claim means filing a complaint in any federal district court, which is then transferred to the District of Arizona MDL. Within the MDL, each plaintiff completes a Plaintiff Fact Sheet (PFS) — a detailed questionnaire documenting the device implantation date, medical history, fracture discovery, injuries sustained, and treatment received. The PFS serves as the primary individual case record during MDL proceedings. Plaintiffs do not attend hearings or appear in Arizona — their attorneys handle all court appearances. Individual plaintiffs receive updates from their attorneys as the MDL progresses through key milestones.
When the MDL reaches a global settlement, each plaintiff's claim is evaluated individually against a settlement compensation matrix that assigns values based on injury severity, age, and other factors. Plaintiffs are not required to accept a global settlement — each plaintiff has the right to opt out and proceed to individual trial. In practice, the overwhelming majority of MDL plaintiffs accept global settlements because they represent fair compensation without the delay and uncertainty of individual trial. Plaintiffs who do not join the MDL and instead pursue state court claims may proceed on a parallel track, though they do not benefit from the MDL's shared discovery resources.
Related Pages
PowerPort Catheter Fracture — How It Happens
Bard PowerPort catheters fracture through a well-documented mechanism called environmental stress cracking (ESC) of polyurethane — a process that was scientifically foreseeable at the time of device design. The fracture is silent and painless, meaning most patients have no idea their catheter has broken until complications force diagnostic imaging.
PowerPort MDL Settlement Timeline — What to Expect
MDL mass tort litigation follows a predictable multi-year progression from case filing through bellwether trials to global settlement. Understanding each phase helps PowerPort plaintiffs set realistic expectations for timing and the factors that determine individual settlement amounts.
PowerPort Catheter Migration — Where Fragments Go
When a PowerPort catheter fractures, the free fragment enters the central venous circulation and travels to the heart and lungs following the path of venous blood flow. The fragment's final resting location determines the severity of injury — from retrievable right-heart positions to life-threatening peripheral pulmonary artery lodgment.
PowerPort vs. Other Port Catheters — Key Differences
The Bard PowerPort's polyurethane catheter is the defining design characteristic that distinguishes it from safer alternatives like Hickman catheters, silicone Mediport devices, and PICC lines — none of which use polyurethane tubing and none of which carry the same environmental stress cracking fracture risk.
PowerPort Removal Surgery — How Fractured Catheters Are Retrieved
Retrieval of a fractured PowerPort catheter fragment requires either percutaneous cardiac catheterization or open thoracic surgery, depending on fragment location and accessibility. The retrieval procedure itself carries procedural risks, and failure to retrieve leaves the patient with an ongoing foreign body infection and cardiac risk.
PowerPort Sepsis and Infection Risk
A fractured PowerPort catheter fragment acts as a permanent intravascular nidus for infection — a foreign body that bacteria colonize with a protective biofilm that antibiotics cannot eradicate without removing the fragment. For immunocompromised cancer patients, this infection risk is particularly life-threatening.
PowerPort Cardiac Perforation — Heart Surgery Risk
Cardiac perforation by a fractured PowerPort catheter fragment is a life-threatening emergency. The thin-walled right ventricle is particularly vulnerable to penetration by a fragment's sharp edge, causing cardiac tamponade — a surgical emergency that can be fatal within minutes without treatment.
Becton Dickinson Liability — BD's Acquisition of Bard
Becton, Dickinson and Company (BD) acquired C.R. Bard in 2017 for $24 billion and assumed full corporate liability for all Bard product claims, including the PowerPort. BD now faces claims not only for Bard's pre-acquisition conduct but also for BD's own post-acquisition decisions to continue selling the PowerPort without redesigning or adequately warning about the fracture risk.
PowerPort Evidence and Records — What You Need for Your Case
Building a strong PowerPort catheter lawsuit requires gathering specific categories of medical and device records. Even if you no longer have the physical device, documentary evidence of the fracture, fragment location, and resulting injury is sufficient to support a claim.
Bard PowerPort Catheter Lawsuit
The Bard PowerPort is an implantable venous access device — a small port placed under the skin, typically in the chest — that allows medical professionals to administer chemotherapy, draw blood, and deliver medications without repeated needle sticks. Millions of patients have received PowerPort devices since C.R. Bard introduced them in the 1990s. The devices are especially common among cancer patients who require long-term intravenous access. Beginning in the early 2010s, patients, physicians, and researchers began documenting a disturbing pattern: the polyurethane catheter tubing attached to the port was fracturing inside the body. Fragments of the catheter — sometimes several centimeters long — were entering the bloodstream and migrating toward the heart and lungs. The resulting complications range from serious to fatal: cardiac perforation, cardiac tamponade, pulmonary embolism, sepsis, and endocarditis. Becton Dickinson (BD) acquired C.R. Bard in 2017 for $24 billion, inheriting both the PowerPort product line and the mounting litigation. In 2022, a federal multidistrict litigation was established in the U.S. District Court for the District of Arizona to consolidate cases nationwide. Legal claims proceed under theories of design defect, manufacturing defect, failure to warn, and negligence. Patients who received a PowerPort catheter and subsequently experienced catheter fracture, fragment migration, infection, cardiac complications, or unexplained symptoms may be entitled to substantial compensation.
View full case overview